News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
FDA
Europe Approves Wyeth’s Enbrel for Psoriasis in Children
January 8, 2009
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
LONDON, Jan 8 (Reuters) - Wyeth's established drug Enbrel has been approved by the European Commission as the first biologic treatment for children with severe plaque psoriasis, the U.S. company said on Thursday.
Twitter
LinkedIn
Facebook
Email
Print
FDA
Approvals
Europe
MORE ON THIS TOPIC
Manufacturing
FDA Launches PreCheck Program, Intended To Bring Manufacturers Home
February 2, 2026
·
2 min read
·
Tristan Manalac
Complete response letters
FDA Warned Corcept of ‘Significant Review Issues’ for Rejected Drug in Early Meetings
February 2, 2026
·
1 min read
·
Tristan Manalac
Regulatory
FDA Action Alert: Sanofi/Regeneron, Merck, REGENXBIO and More
February 2, 2026
·
7 min read
·
Tristan Manalac
Cancer
FDA’s Multiple Myeloma Guidance Highlights Decade of Success
January 30, 2026
·
4 min read
·
Dan Samorodnitsky
